We are a pre-clinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. 

OK-101, our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as dry eye disease, or DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. The disease affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected. Prevalence of DED is anticipated to increase substantially in the next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare.

At present, there are essentially three major prescription drugs used to treat DED: 1) Restasis (cyclosporine), 2) Xiidra (lifitegrast), and 3) Tyrvaya (Varenicline). However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available to them through the medical community. 

**Note: Net loss is for the year ended March 31, 2021, according to the prospectus.

(Note: OKYO Pharma Ltd. priced its IPO on May 16, 2022, by increasing the number of American Depositary Shares (ADS) to 625,000 ADS, up from 513,000 ADS in its prospectus, and cutting the price to $4.00, down from $4.92 per ADS in its F-1/A filing dated May 13, 2022. This IPO raised $2.5 million. The deal’s terms had been revised many times – the May 13, 2022, downsizing to 513,000 ADS at $4.92 each; previously the IPO was cut in half to 1.0 million ADS at $5.20 each, according to an F-1/A filing dated April 26, 2022.)